ArticleCureus2025
Omalizumab Therapy for Bullous Pemphigoid: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is a chronic autoimmune blistering disease characterized by the presence of autoantibodies that target hemidesmosomal proteins, specifically BP180 and BP230. This immune response leads to the formation of subepidermal blisters and inflammation. The primary treatment for BP involves systemic corticosteroids; however, long-term use can result in significant adverse effects, and some patients may experience resistance to steroid therapy. We report the case of a 62-year-old male with multiple comorbidities who developed progressive, itchy blisters and extensive skin erosions affecting more than 50% of his body surface. Although he initially showed improvement with intravenous corticosteroids, new blister formation continued, and Staphylococcus aureus bacteremia prevented further use of immunosuppressive therapy. The patient was managed with targeted antibiotics, intravenous immunoglobulin (IVIG), and omalizumab. This treatment resulted in significant clinical improvement, the resolution of new blister formation, and a successful tapering of corticosteroids. Omalizumab has demonstrated promising efficacy in treating BP, especially in refractory cases. Given its favorable safety profile, further clinical trials are needed to determine its long-term role in the management of BP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.